Breakthrough Preclinical Data for SLS009 in Acute Myeloid Leukemia Unveiled

San Diego, Monday, 28 April 2025.
SELLAS presents promising preclinical results for SLS009, showing up to 97% reduction in TP53-mutated leukemia cells, marking a significant advancement in AML treatment strategies.